Congratulations to Fisher Lab @ucl.ac.uk on predicting combinations of anticancer drugs, was privileged to be part of the consortium. Executable models offer insights that black box models do not. pubmed.ncbi.nlm.nih.gov/42341181/ @icr.ac.uk @crukconvergence.bsky.social

Research can be all consuming, sometimes you have to stop and look around.....

Proximity induced degradation has only just begun!

American Association for Cancer Research (AACR)@theaacr.bsky.social · 3mo ago

The @US_FDA approved the protein degrader vepdegestrant for adults with previously treated ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations: buff.ly/B0gPzIW

The intersection of the PI3K/AKT pathway and immunotherapy. ICECAP study led by Prof Juanita Lopez. pubmed.ncbi.nlm.nih.gov/42043781/ @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social

At #AACR26. Leveraging cancer stroma to deliver anticancer drugs. Fibroblast co-culture experiments in PDAC and sarcoma cell lines to study the role of AVA6000 a FAP activated doxorubicin prodrug as a single agent and in combination. @icr.ac.uk @crukconvergence.bsky.social

At #AACR26 Poster 6457.CD137 agonist. Exciting responses in breast cancer and high spec pharmacodynamic imaging showing decreasing metabolism (FDG-PET) but increasing lymphocytic infiltration (CD8 PET). @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social

At ##AACR26 , great to see the Cancer Therapeutics podium filled by ex Drug Development Unit fellows who are now Profs all across the world! @icr.ac.uk @royalmarsden.org . 👏👏👏

Its a honour to be appointed as a NIHR Senior Investigator. The NIHR has kept research at the forefront of the NHS and allows us to perform patient centric, scientifically robust research. @icr.ac.uk @royalmarsden.org @nihr.bsky.social

Seville (bitter) oranges some times used for marmalade or juice but not usually edible as an oranges contain furanocumarins, CYP3A4 inhibitors that increase levels of drugs metabolised by CYP3A4.

Fuelling the qest for the next generation of clinician scientists. Great opportunity!

CRUK Convergence Science Centre@crukconvergence.bsky.social · 9mo ago

❗One week left to apply for our intercalated #PhD (iPhD) ⌛ If you're a medical student interested in becoming a clinician-scientist, check out our PhD projects for 2026. 👇

PhD convocation ceremony at @icr.ac.uk with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised. @trevorgraham.bsky.social

Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records. pubmed.ncbi.nlm.nih.gov/40855012/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social @nihr.bsky.social

Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite. pubmed.ncbi.nlm.nih.gov/40641211/ @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social

Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads. pubmed.ncbi.nlm.nih.gov/40611310/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social

Published today @natmed.nature.com www.nature.com/articles/s41... Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social‬ ‪@icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social‬ @nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org ‪

Published today in @natmed.nature.com www.nature.com/articles/s41... combination of avutometinib and defactinib in LGSOC. @icr.ac.uk‬ @icrdduiit.bsky.social‬ @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social @nihr.bsky.social‬ ‪@crukconvergence.bsky.social @cancerresearchuk.org ‪

#MCCR2025. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC @theaacr.bsky.social

Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients. @ecmc.bsky.social @icr.ac.uk @icrdduiit.bsky.social @nihr.bsky.social @cruk.bsky.social

Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer. #AACR2025 @icr.ac.uk

End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need. @icr.ac.uk @crukconvergence.bsky.social @nihr.bsky.social @ecmc-uk.bsky.social

Masterclass in next generation ADCs! ED11 #AACR2025 worth watching online if you missed it.

Only at #AACR 2025, Love the commitment!!!

#AACR2025 has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz! @icr.ac.uk @cancerresearchuk.org @nihr.bsky.social

Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!

www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…

Unfolded protein response meets AR transcription. We need to think out the box to tackle known oncogenic drivers. Great piece of work from my colleague @AdamSharpMedOnc out this week aacrjournals.org/clincancerre... @icrlondon.bsky.social @theaacr.bsky.social

NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth

Abstract. Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men w...

aacrjournals.org

Very interesting personalized m-RNA cancer vaccine paper in nature medicine www.nature.com/articles/s41... published this week establishing proof concept of the technology. Trial was led by my colleague Juantia Lopez and our unit was involved as part of an international clinical trial.

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial - Nature Medicine

In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in comb...

nature.com